Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Bekoz H., Karadurmus N., PAYDAŞ S., TÜRKER A., TOPTAŞ T., Tuglular T. F., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.28, sa.10, ss.2496-2502, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 10
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1093/annonc/mdx341
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2496-2502
  • Anahtar Kelimeler: Hodgkin lymphoma, resistant/relapsed disease, programmed death 1 (PD-1) blocker, nivolumab, BRENTUXIMAB VEDOTIN, PD-1 BLOCKADE
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.